Fresenius Medical Care AG & Co. KGaA (FMCQF)
| Previous close | 79.91 |
| Open | 79.91 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 79.91 - 79.91 |
| 52-week range | 68.34 - 89.71 |
| Volume | 9 |
| Avg. volume | 2,776 |
| Market cap | 23.405B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 17.44 |
| EPS (TTM) | 4.58 |
| Earnings date | N/A |
| Forward dividend & yield | 1.64 (2.05%) |
| Ex-dividend date | 24 May 2021 |
| 1y target est | N/A |
- Zacks
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
- EQS Group
Fresenius Medical Care AG & Co. KGaA reports results in line with expectations for the second quarter and confirms 2021 outlook
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Half Year Results30.07.2021 / 07:03 The issuer is solely responsible for the content of this announcement. As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses Patient excess mortality rates significantly reduced Negative exchange rate effects continue Earnings development impacted by phasing and strong prior-year base, as indicated Financial targets for FY 2021 confirmed FME25 progra
- Zacks
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
